SG184155A1 - Ectodomains of influenza matrix 2 protein, expression system, and uses thereof - Google Patents

Ectodomains of influenza matrix 2 protein, expression system, and uses thereof Download PDF

Info

Publication number
SG184155A1
SG184155A1 SG2012069555A SG2012069555A SG184155A1 SG 184155 A1 SG184155 A1 SG 184155A1 SG 2012069555 A SG2012069555 A SG 2012069555A SG 2012069555 A SG2012069555 A SG 2012069555A SG 184155 A1 SG184155 A1 SG 184155A1
Authority
SG
Singapore
Prior art keywords
seq
polypeptide
polynucleotide
vector
influenza
Prior art date
Application number
SG2012069555A
Other languages
English (en)
Inventor
Tina Guina
Michael Lacy
Mario Skiadopoulos
Nutan Mytle
Original Assignee
Emergent Product Dev Gaithersburg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Gaithersburg Inc filed Critical Emergent Product Dev Gaithersburg Inc
Publication of SG184155A1 publication Critical patent/SG184155A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG2012069555A 2010-03-26 2011-03-28 Ectodomains of influenza matrix 2 protein, expression system, and uses thereof SG184155A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31823210P 2010-03-26 2010-03-26
PCT/US2011/030205 WO2011120045A1 (en) 2010-03-26 2011-03-28 Ectodomains of influenza matrix 2 protein, expression system, and uses thereof

Publications (1)

Publication Number Publication Date
SG184155A1 true SG184155A1 (en) 2012-10-30

Family

ID=44673677

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012069555A SG184155A1 (en) 2010-03-26 2011-03-28 Ectodomains of influenza matrix 2 protein, expression system, and uses thereof

Country Status (8)

Country Link
US (1) US20130115234A1 (https=)
EP (1) EP2552490A4 (https=)
JP (1) JP2013523096A (https=)
CN (1) CN103118709A (https=)
AU (1) AU2011230491A1 (https=)
CA (1) CA2793772A1 (https=)
SG (1) SG184155A1 (https=)
WO (1) WO2011120045A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015006384A1 (en) * 2013-07-09 2015-01-15 Texas Tech University System Universal influenza vaccine
CN105002149B (zh) * 2014-04-22 2018-04-06 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
CN105018441A (zh) * 2014-04-22 2015-11-04 中国科学院生物物理研究所 流感病毒rna聚合酶结晶的方法
WO2016131945A1 (en) * 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2016176761A1 (en) * 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
BR112019013724A2 (pt) * 2017-01-03 2020-04-14 Emergex Vaccines Holding Limited composições de vacina influenza universal
CN108373507A (zh) * 2018-01-18 2018-08-07 复旦大学 一种重组亚单位禽流感疫苗Sef4M2e
EP4626470A2 (en) * 2022-11-29 2025-10-08 The Scripps Research Institute Vaccines containing novel nanoparticle scaffolds
WO2024196719A2 (en) * 2023-03-17 2024-09-26 Versatope Therapeutics, Inc. Membrane vesicles comprising multiple influenza antigens for vaccines
CN118530314B (zh) * 2024-06-06 2025-09-30 中国科学院武汉病毒研究所 广谱型流感疫苗抗原片段、重组益生菌及应用
CN119350508A (zh) * 2024-10-22 2025-01-24 成都纳微金生物技术有限公司 带广谱表位的三价流感纳米颗粒疫苗及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
CN102703393A (zh) * 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7354589B2 (en) * 2003-01-16 2008-04-08 The Wistar Institute Multiple antigenic agents and methods for using the same
CN1280310C (zh) * 2004-09-29 2006-10-18 清华大学 具有防治流感作用的融合蛋白及其编码基因与应用
EP1819732A2 (en) * 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
NZ556004A (en) * 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
KR20100075843A (ko) * 2007-08-21 2010-07-05 다이나박스 테크놀로지 코퍼레이션 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법
AU2008293504B2 (en) * 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
CN101531719B (zh) * 2008-06-06 2011-09-14 江苏省农业科学院 一种禽流感基因工程多肽抗原
CN101643721B (zh) * 2009-08-17 2011-05-25 诺华生物科技(武汉)有限责任公司 广谱安全型动物用抗甲型流感病毒疫苗

Also Published As

Publication number Publication date
CA2793772A1 (en) 2011-09-29
EP2552490A1 (en) 2013-02-06
WO2011120045A1 (en) 2011-09-29
CN103118709A (zh) 2013-05-22
AU2011230491A1 (en) 2012-10-18
US20130115234A1 (en) 2013-05-09
EP2552490A4 (en) 2013-12-18
JP2013523096A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
US20130115234A1 (en) Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
US20250367278A1 (en) Variant strain-based coronavirus vaccines
AU2016342048B2 (en) Broad spectrum influenza virus vaccine
US8288090B2 (en) Influenza vaccines
US9388220B2 (en) Immunogenic compositions and methods
US20200030432A1 (en) Zoonotic disease rna vaccines
CN102257135B (zh) 流感疫苗的生产
EP2670430B1 (en) Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
US20110020391A1 (en) Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
Stachyra et al. DNA vaccines against influenza.
US20110159031A1 (en) Vaccine to Influenza A Virus
CN101484466A (zh) 针对流感病毒的抗病毒剂和疫苗
CN102740880A (zh) 基于重组修饰的安卡拉痘苗(mva)病毒的通用流感疫苗
US20260041761A1 (en) Pharmaceutical composition for resisting infection with sars-cov-2 or mutant thereof, and combined drug thereof
US9963490B2 (en) Influenza nucleoprotein vaccines
CN119039453A (zh) 一种痘病毒单链融合免疫原、包含其的免疫原性组合物及其应用
US20220275346A1 (en) Hantavirus antigenic composition
WO2010005474A1 (en) Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens
CN119039454A (zh) 痘病毒重组嵌合抗原、其疫苗组合物及其应用
US20130243808A1 (en) Compositions and methods for vaccinating humans and animals against enveloped viruses
HK1183791A (en) Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
WO2014145261A2 (en) Methods and compositions for in vivo immune stimulation and antigen production
Hussein et al. Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus